Document Type : Short Communications
Authors
1
Department of Radiology, Division of Nuclear Medicine and Theranostic Moleculer, Faculty of Medicine, Universitas Andalas/Dr.M.Djamil Hospital, Padang, 25127, Indonesia.
2
Faculty of Medicine, Universitas Andalas, Unand Limau Manis, Padang, Indonesia.
3
Department of Surgery, Faculty of Medicine, Universitas Andalas/Dr.M.Djamil Hospital, Padang, Indonesia.
4
Department of Ear, Nose and Throat, Faculty of Medicine, Universitas Andalas, Padang/Dr.M.Djamil, Padang, Indonesia.
5
Department of Physiology, Universitas Andalas, Padang, 25127, Indonesia.
Abstract
Iodine intake can affect thyroid and breast cells, and urinary iodine concentration (UIC) is an effective biomarker for iodine intake. Objectives: This study aimed to analyze the correlation between urinary iodine concentration in differentiated thyroid cancer (DTC) and breast cancer (BC) subjects. Methods: The study consisted of 80 subjects divided into case (20 DTC and 20 BC subjects) and control (40 subjects). Morning urine or spot urine was used for UIC measurement. Results: In thyroid cancer, UIC median patients and controls were 195.45 ± 133.61 µg/L and 145 ± 39.64 µg/L, respectively, with p =0.33. The UIC median of PTC subjects was significantly higher compared to FTC subjects, 227.12±130.98 μg/L versus 68.75±22.95 μg/L, p=0.00, and papillary thyroid cancer is closely related to a high iodine excretion in urine with contingency coefficient (c)=0.722. In BC patients, regardless of subtypes, breast cancer subjects showed a significantly lower iodine excretion level. The median of UIC patients and controls were 80.05 ± 38.24 µg/L and 144.25 ± 36.79 µg/L, respectively, p=0.000. Conclusions: Iodine urine concentrations strongly correlate with the type of DTC histopathology, and in BC subjects, IUC was significantly lower compared to the control.
Keywords
Main Subjects
)